nodes	percent_of_prediction	percent_of_DWPC	metapath
Mupirocin—IARS—neck—thyroid cancer	0.0956	0.358	CbGeAlD
Mupirocin—IARS—trachea—thyroid cancer	0.0575	0.215	CbGeAlD
Mupirocin—Furuncle—Vandetanib—thyroid cancer	0.0514	0.0701	CcSEcCtD
Mupirocin—IARS—thyroid gland—thyroid cancer	0.0455	0.17	CbGeAlD
Mupirocin—IARS—head—thyroid cancer	0.0404	0.151	CbGeAlD
Mupirocin—IARS—lymph node—thyroid cancer	0.0283	0.106	CbGeAlD
Mupirocin—Cellulitis—Vandetanib—thyroid cancer	0.0277	0.0378	CcSEcCtD
Mupirocin—Sensitisation—Epirubicin—thyroid cancer	0.0176	0.024	CcSEcCtD
Mupirocin—Dry skin—Vandetanib—thyroid cancer	0.0168	0.0229	CcSEcCtD
Mupirocin—Sensitisation—Doxorubicin—thyroid cancer	0.0163	0.0222	CcSEcCtD
Mupirocin—Mouth ulceration—Sorafenib—thyroid cancer	0.0154	0.021	CcSEcCtD
Mupirocin—Furunculosis—Epirubicin—thyroid cancer	0.0148	0.0202	CcSEcCtD
Mupirocin—Eczema—Sorafenib—thyroid cancer	0.0137	0.0187	CcSEcCtD
Mupirocin—Furunculosis—Doxorubicin—thyroid cancer	0.0137	0.0186	CcSEcCtD
Mupirocin—Ulcerative stomatitis—Epirubicin—thyroid cancer	0.0136	0.0186	CcSEcCtD
Mupirocin—Epistaxis—Vandetanib—thyroid cancer	0.0133	0.0181	CcSEcCtD
Mupirocin—Dermatitis exfoliative—Sorafenib—thyroid cancer	0.0131	0.0178	CcSEcCtD
Mupirocin—Furuncle—Epirubicin—thyroid cancer	0.0128	0.0175	CcSEcCtD
Mupirocin—Haemoglobin—Vandetanib—thyroid cancer	0.0127	0.0173	CcSEcCtD
Mupirocin—Haemorrhage—Vandetanib—thyroid cancer	0.0126	0.0173	CcSEcCtD
Mupirocin—Ulcerative stomatitis—Doxorubicin—thyroid cancer	0.0126	0.0172	CcSEcCtD
Mupirocin—Furuncle—Doxorubicin—thyroid cancer	0.0118	0.0162	CcSEcCtD
Mupirocin—Dry skin—Sorafenib—thyroid cancer	0.0113	0.0154	CcSEcCtD
Mupirocin—Dysgeusia—Vandetanib—thyroid cancer	0.0108	0.0147	CcSEcCtD
Mupirocin—Cough—Vandetanib—thyroid cancer	0.00961	0.0131	CcSEcCtD
Mupirocin—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00931	0.0127	CcSEcCtD
Mupirocin—Dry mouth—Vandetanib—thyroid cancer	0.00917	0.0125	CcSEcCtD
Mupirocin—Epistaxis—Sorafenib—thyroid cancer	0.00896	0.0122	CcSEcCtD
Mupirocin—Skin disorder—Vandetanib—thyroid cancer	0.00873	0.0119	CcSEcCtD
Mupirocin—Haemoglobin—Sorafenib—thyroid cancer	0.00857	0.0117	CcSEcCtD
Mupirocin—Haemorrhage—Sorafenib—thyroid cancer	0.00853	0.0116	CcSEcCtD
Mupirocin—Stinging—Epirubicin—thyroid cancer	0.00775	0.0106	CcSEcCtD
Mupirocin—Immune system disorder—Sorafenib—thyroid cancer	0.00771	0.0105	CcSEcCtD
Mupirocin—Pain—Vandetanib—thyroid cancer	0.00768	0.0105	CcSEcCtD
Mupirocin—Erythema—Sorafenib—thyroid cancer	0.00743	0.0101	CcSEcCtD
Mupirocin—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00735	0.01	CcSEcCtD
Mupirocin—Dysgeusia—Sorafenib—thyroid cancer	0.00727	0.00992	CcSEcCtD
Mupirocin—Stinging—Doxorubicin—thyroid cancer	0.00717	0.00978	CcSEcCtD
Mupirocin—Abdominal pain—Vandetanib—thyroid cancer	0.0071	0.00969	CcSEcCtD
Mupirocin—Cellulitis—Epirubicin—thyroid cancer	0.0069	0.00942	CcSEcCtD
Mupirocin—Angioedema—Sorafenib—thyroid cancer	0.00679	0.00926	CcSEcCtD
Mupirocin—Cough—Sorafenib—thyroid cancer	0.00648	0.00884	CcSEcCtD
Mupirocin—Cellulitis—Doxorubicin—thyroid cancer	0.00639	0.00872	CcSEcCtD
Mupirocin—Pruritus—Vandetanib—thyroid cancer	0.00636	0.00867	CcSEcCtD
Mupirocin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00628	0.00857	CcSEcCtD
Mupirocin—Dermatitis contact—Epirubicin—thyroid cancer	0.0062	0.00847	CcSEcCtD
Mupirocin—Dry mouth—Sorafenib—thyroid cancer	0.00618	0.00844	CcSEcCtD
Mupirocin—Diarrhoea—Vandetanib—thyroid cancer	0.00615	0.00839	CcSEcCtD
Mupirocin—Anaphylactic shock—Sorafenib—thyroid cancer	0.00606	0.00827	CcSEcCtD
Mupirocin—Dizziness—Vandetanib—thyroid cancer	0.00594	0.00811	CcSEcCtD
Mupirocin—Skin disorder—Sorafenib—thyroid cancer	0.00589	0.00803	CcSEcCtD
Mupirocin—Dermatitis contact—Doxorubicin—thyroid cancer	0.00574	0.00783	CcSEcCtD
Mupirocin—Mouth ulceration—Epirubicin—thyroid cancer	0.00568	0.00775	CcSEcCtD
Mupirocin—Rash—Vandetanib—thyroid cancer	0.00567	0.00773	CcSEcCtD
Mupirocin—Dermatitis—Vandetanib—thyroid cancer	0.00566	0.00772	CcSEcCtD
Mupirocin—Headache—Vandetanib—thyroid cancer	0.00563	0.00768	CcSEcCtD
Mupirocin—Nausea—Vandetanib—thyroid cancer	0.00534	0.00728	CcSEcCtD
Mupirocin—Mouth ulceration—Doxorubicin—thyroid cancer	0.00525	0.00717	CcSEcCtD
Mupirocin—Pain—Sorafenib—thyroid cancer	0.00518	0.00707	CcSEcCtD
Mupirocin—Eczema—Epirubicin—thyroid cancer	0.00507	0.00692	CcSEcCtD
Mupirocin—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00496	0.00676	CcSEcCtD
Mupirocin—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.00483	0.00659	CcSEcCtD
Mupirocin—Urticaria—Sorafenib—thyroid cancer	0.00482	0.00657	CcSEcCtD
Mupirocin—Abdominal pain—Sorafenib—thyroid cancer	0.00479	0.00654	CcSEcCtD
Mupirocin—Eczema—Doxorubicin—thyroid cancer	0.00469	0.0064	CcSEcCtD
Mupirocin—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.00447	0.0061	CcSEcCtD
Mupirocin—Hypersensitivity—Sorafenib—thyroid cancer	0.00447	0.00609	CcSEcCtD
Mupirocin—Pruritus—Sorafenib—thyroid cancer	0.00429	0.00585	CcSEcCtD
Mupirocin—Dry skin—Epirubicin—thyroid cancer	0.00418	0.0057	CcSEcCtD
Mupirocin—Diarrhoea—Sorafenib—thyroid cancer	0.00415	0.00566	CcSEcCtD
Mupirocin—Dizziness—Sorafenib—thyroid cancer	0.00401	0.00547	CcSEcCtD
Mupirocin—Dry skin—Doxorubicin—thyroid cancer	0.00387	0.00527	CcSEcCtD
Mupirocin—Rash—Sorafenib—thyroid cancer	0.00382	0.00521	CcSEcCtD
Mupirocin—Dermatitis—Sorafenib—thyroid cancer	0.00382	0.00521	CcSEcCtD
Mupirocin—Headache—Sorafenib—thyroid cancer	0.0038	0.00518	CcSEcCtD
Mupirocin—Nausea—Sorafenib—thyroid cancer	0.0036	0.00491	CcSEcCtD
Mupirocin—Epistaxis—Epirubicin—thyroid cancer	0.00331	0.00452	CcSEcCtD
Mupirocin—Haemoglobin—Epirubicin—thyroid cancer	0.00317	0.00432	CcSEcCtD
Mupirocin—Rhinitis—Epirubicin—thyroid cancer	0.00316	0.00431	CcSEcCtD
Mupirocin—Haemorrhage—Epirubicin—thyroid cancer	0.00315	0.0043	CcSEcCtD
Mupirocin—Pharyngitis—Epirubicin—thyroid cancer	0.00313	0.00427	CcSEcCtD
Mupirocin—Epistaxis—Doxorubicin—thyroid cancer	0.00307	0.00418	CcSEcCtD
Mupirocin—Haemoglobin—Doxorubicin—thyroid cancer	0.00293	0.004	CcSEcCtD
Mupirocin—Rhinitis—Doxorubicin—thyroid cancer	0.00292	0.00399	CcSEcCtD
Mupirocin—Haemorrhage—Doxorubicin—thyroid cancer	0.00292	0.00398	CcSEcCtD
Mupirocin—Pharyngitis—Doxorubicin—thyroid cancer	0.0029	0.00395	CcSEcCtD
Mupirocin—Immune system disorder—Epirubicin—thyroid cancer	0.00285	0.00389	CcSEcCtD
Mupirocin—Erythema—Epirubicin—thyroid cancer	0.00274	0.00375	CcSEcCtD
Mupirocin—Dysgeusia—Epirubicin—thyroid cancer	0.00269	0.00367	CcSEcCtD
Mupirocin—Immune system disorder—Doxorubicin—thyroid cancer	0.00264	0.0036	CcSEcCtD
Mupirocin—Erythema—Doxorubicin—thyroid cancer	0.00254	0.00347	CcSEcCtD
Mupirocin—Dysgeusia—Doxorubicin—thyroid cancer	0.00249	0.00339	CcSEcCtD
Mupirocin—Cough—Epirubicin—thyroid cancer	0.0024	0.00327	CcSEcCtD
Mupirocin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00232	0.00317	CcSEcCtD
Mupirocin—Dry mouth—Epirubicin—thyroid cancer	0.00229	0.00312	CcSEcCtD
Mupirocin—Anaphylactic shock—Epirubicin—thyroid cancer	0.00224	0.00306	CcSEcCtD
Mupirocin—Cough—Doxorubicin—thyroid cancer	0.00222	0.00302	CcSEcCtD
Mupirocin—Skin disorder—Epirubicin—thyroid cancer	0.00218	0.00297	CcSEcCtD
Mupirocin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00215	0.00293	CcSEcCtD
Mupirocin—Dry mouth—Doxorubicin—thyroid cancer	0.00211	0.00289	CcSEcCtD
Mupirocin—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00207	0.00283	CcSEcCtD
Mupirocin—Skin disorder—Doxorubicin—thyroid cancer	0.00201	0.00275	CcSEcCtD
Mupirocin—Pain—Epirubicin—thyroid cancer	0.00192	0.00261	CcSEcCtD
Mupirocin—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00183	0.0025	CcSEcCtD
Mupirocin—Urticaria—Epirubicin—thyroid cancer	0.00178	0.00243	CcSEcCtD
Mupirocin—Pain—Doxorubicin—thyroid cancer	0.00177	0.00242	CcSEcCtD
Mupirocin—Abdominal pain—Epirubicin—thyroid cancer	0.00177	0.00242	CcSEcCtD
Mupirocin—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00169	0.00231	CcSEcCtD
Mupirocin—Hypersensitivity—Epirubicin—thyroid cancer	0.00165	0.00225	CcSEcCtD
Mupirocin—Urticaria—Doxorubicin—thyroid cancer	0.00165	0.00225	CcSEcCtD
Mupirocin—Abdominal pain—Doxorubicin—thyroid cancer	0.00164	0.00224	CcSEcCtD
Mupirocin—Pruritus—Epirubicin—thyroid cancer	0.00158	0.00216	CcSEcCtD
Mupirocin—Diarrhoea—Epirubicin—thyroid cancer	0.00153	0.00209	CcSEcCtD
Mupirocin—Hypersensitivity—Doxorubicin—thyroid cancer	0.00153	0.00208	CcSEcCtD
Mupirocin—Dizziness—Epirubicin—thyroid cancer	0.00148	0.00202	CcSEcCtD
Mupirocin—Pruritus—Doxorubicin—thyroid cancer	0.00147	0.002	CcSEcCtD
Mupirocin—Diarrhoea—Doxorubicin—thyroid cancer	0.00142	0.00194	CcSEcCtD
Mupirocin—Rash—Epirubicin—thyroid cancer	0.00141	0.00193	CcSEcCtD
Mupirocin—Dermatitis—Epirubicin—thyroid cancer	0.00141	0.00193	CcSEcCtD
Mupirocin—Headache—Epirubicin—thyroid cancer	0.0014	0.00191	CcSEcCtD
Mupirocin—Dizziness—Doxorubicin—thyroid cancer	0.00137	0.00187	CcSEcCtD
Mupirocin—Nausea—Epirubicin—thyroid cancer	0.00133	0.00182	CcSEcCtD
Mupirocin—Rash—Doxorubicin—thyroid cancer	0.00131	0.00178	CcSEcCtD
Mupirocin—Dermatitis—Doxorubicin—thyroid cancer	0.00131	0.00178	CcSEcCtD
Mupirocin—Headache—Doxorubicin—thyroid cancer	0.0013	0.00177	CcSEcCtD
Mupirocin—Nausea—Doxorubicin—thyroid cancer	0.00123	0.00168	CcSEcCtD
